TABLE 1.
Demographic and Clinical Characteristics of Study Subjects Classified by Thal Amyloid Stages
|
Thal amyloid stages
|
Total (column %) | ||||
|---|---|---|---|---|---|
| 0 | 1/2 | 3 | 4/5 | ||
| Number (row %) | 13 (6.8) | 17 (8.9) | 22 (11.5) | 140 (72.9) | 192 (100.0) |
| Sex | |||||
| n male (row %) | 8 (7.6) | 9 (8.6) | 12 (11.4) | 76 (72.4) | 105 (54.7) |
| n female (row %) | 5 (5.8) | 8 (9.2) | 10 (11.5) | 64 (73.6) | 87 (45.3) |
| Education (y) | 16.0 ± 2.7 | 15.3 ± 2.5 | 16.0 ± 3.1 | 15.3 ± 3.5 | 15.4 ± 3.3 |
| Age at death (y) | 89.4 ± 8.4 | 84.0 ± 9.9 | 85.1 ± 7.9 | 79.6 ± 10.5 | 81.3 ± 10.4 |
| Age at onset (y) | |||||
| n (row %) | 9 (5.4) | 12 (7.2) | 16 (9.6) | 130 (77.8) | 167 (100.0) |
| Mean ± SD | 81.4 ± 11.3 | 76.1 ± 11.1 | 79.5 ± 10.9 | 69.0 ± 10.7 | 71.2 ± 11.5 |
| Symptom duration (y) | |||||
| n (row %) | 9 (5.4) | 12 (7.2) | 16 (9.6) | 130 (77.8) | 167 (100.0) |
| Mean ± SD | 8.0 ± 4.0 | 7.6 ± 2.6 | 7.4 ± 5.7 | 9.8 ± 4.5 | 9.3 ± 4.5 |
| Time from last evaluation to death (mo) | 7.1 ± 4.0 | 11.1 ± 7.7 | 8.7 ± 5.0 | 8.7 ± 5.9 | 8.8 ± 5.9 |
| APOE genotype, n (row %) | |||||
| ϵ2/ϵ3 | 2 (16.7) | 1 (8.3) | 3 (25.0) | 6 (50.0) | 12 (7.8) |
| ϵ2/ϵ4 | 0 (0.0) | 0 (0.0) | 1 (33.3) | 2 (66.7) | 3 (2.0) |
| ϵ3/ϵ3 | 7 (9.3) | 11 (14.7) | 11 (14.7) | 46 (61.3) | 75 (49.0) |
| ϵ3/ϵ4 | 0 (0.0) | 3 (6.0) | 4 (8.0) | 43 (86.0) | 50 (32.7) |
| ϵ4/ϵ4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (100.0) | 13 (8.5) |
| Missing/unknown/not assessed | 4 (10.3) | 2 (5.1) | 3 (7.7) | 30 (76.9) | |
Education, age at death and onset, symptom duration, and time from last evaluation to death are expressed as mean ± SD. Numbers in parentheses represent row percentages unless otherwise indicated. Some values for age at onset and symptom duration were missing; therefore, numbers of subjects with available data are reported.
y, years; mo, months; n, number.